Yency Johana Forero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yency Johana Forero has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Eric L. Grogan
Vanderbilt University Medical Center, Nashville, Tennessee
10 shared publications - Fabien Maldonado
Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
10 shared publications - Kevin Connor McGann
Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN
10 shared publications - Timothy A. Khalil
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
9 shared publications - Anna E. Baron
15Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado
8 shared publications - Camden Lopez
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) of individual biomarkers compared to the combined 4-marker model in Train+Test.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) of individual biomarkers compared to the combined 4-marker model in Train+Test.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Distribution of biomarker levels for benign and malignant pulmonary nodules in the Train (A, n=371, 54% malignant) and Test (B, n=166, 44% malignant) cohorts. Brackets show the corresponding p value statistic for the t-test by biomarker.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Distribution of biomarker levels for benign and malignant pulmonary nodules in the Train (A, n=371, 54% malignant) and Test (B, n=166, 44% malignant) cohorts. Brackets show the corresponding p value statistic for the t-test by biomarker.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort composition by participating EDRN site.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort composition by participating EDRN site.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) and the sensitivity and specificity for the categorical thresholds (e.g., positive cutoffs) of each biomarker as given by the Youden’s Index test. Values are shown with their associated 95% confidence interval given in parentheses.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Area under the receiver operating characteristic curve (AUC) and the sensitivity and specificity for the categorical thresholds (e.g., positive cutoffs) of each biomarker as given by the Youden’s Index test. Values are shown with their associated 95% confidence interval given in parentheses.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort demographic data. ‘COPD’ = chronic obstructive pulmonary disease. ‘Lung carcinogen exposure’ defined as >8hr/wk. of exposure to a known pulmonary carcinogen for at least 1 yr.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
LTP-2 cohort demographic data. ‘COPD’ = chronic obstructive pulmonary disease. ‘Lung carcinogen exposure’ defined as >8hr/wk. of exposure to a known pulmonary carcinogen for at least 1 yr.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Study flow diagram of the process for prospective specimen collection on the internal training, external testing, and external validation cohorts, in addition to the subsequent biomarker measurement and analysis.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Study flow diagram of the process for prospective specimen collection on the internal training, external testing, and external validation cohorts, in addition to the subsequent biomarker measurement and analysis.
- Open Access
- 23 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0341522
Longitudinal analysis of CYFRA 21-1 levels in patients with pulmonary nodules: Differential trajectories between benign and malignant cases
Background: CYFRA 21−1, a cytokeratin-19 fragment, is a validated serum biomarker for non-small cell lung cancer (NSCLC). However, most studies rely on single time-point measurements, limiting its specificity in differentiating malignancy from benign pulmonary conditions. Inspired by the clinical utility of serial PSA measurements in prostate cancer, we investigated whether longitudinal trends in CYFRA 21−1 could enhance diagnostic and monitoring capabilities in patients with pulmonary nodules. Methods and Findings: We analyzed 132 patients with pulmonary nodules from the Vanderbilt Thoracic Biorepository. For the primary analysis, patients who underwent treatment prior to biomarker assessment were excluded, resulting in an untreated cohort of 121 patients (91 benign and 30 malignant nodules). CYFRA 21−1 levels were measured serially using electrochemiluminescence assays. Longitudinal trends were assessed using linear mixed-effects models to estimate biomarker trajectories. Primary analyses compared benign vs. malignant nodules using longitudinal modeling of log-transformed CYFRA 21−1 values. At baseline, CYFRA 21−1 levels were significantly higher in malignant versus benign nodules. Longitudinal mixed-effects modeling did not demonstrate statistically significant differences in trajectories between benign and malignant nodules. Benign nodules showed a small positive trend in log(CYFRA 21−1) whereas malignant nodules showed greater longitudinal variability. The magnitude of change assessed using the absolute slope of log(CYFRA 21−1) was significantly greater in malignant nodules compared with benign nodules (p < 0.05). Exploratory diagnostic analysis showed that baseline log(CYFRA 21−1) achieved and AUC of 0.68 (95% CI 0.56-0.79) with sensitivity 0.63 and specificity 0.71. The absolute slope of log(CYFRA 21−1) yielded an AUC of 0.67 (95% CI 0.48-0.87) with sensitivity 0.39 and specificity 0.97. Conclusions: CYFRA 21−1 exhibits substantial within-patient variability over time, with trajectories that reflect disease state and treatment. These findings suggest that longitudinal monitoring of CYFRA 21−1 may provide additional information beyond single time-point measurements in the evaluation of pulmonary nodules. Further studies in large prospective cohorts are warranted to validate these findings before clinical implementation.
- 23 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0341522
Open AccessLongitudinal analysis of CYFRA 21-1 levels in patients with pulmonary nodules: Differential trajectories between benign and malignant cases
Background: CYFRA 21−1, a cytokeratin-19 fragment, is a validated serum biomarker for non-small cell lung cancer (NSCLC). However, most studies rely on single time-point measurements, limiting its specificity in differentiating malignancy from benign pulmonary conditions. Inspired by the clinical utility of serial PSA measurements in prostate cancer, we investigated whether longitudinal trends in CYFRA 21−1 could enhance diagnostic and monitoring capabilities in patients with pulmonary nodules. Methods and Findings: We analyzed 132 patients with pulmonary nodules from the Vanderbilt Thoracic Biorepository. For the primary analysis, patients who underwent treatment prior to biomarker assessment were excluded, resulting in an untreated cohort of 121 patients (91 benign and 30 malignant nodules). CYFRA 21−1 levels were measured serially using electrochemiluminescence assays. Longitudinal trends were assessed using linear mixed-effects models to estimate biomarker trajectories. Primary analyses compared benign vs. malignant nodules using longitudinal modeling of log-transformed CYFRA 21−1 values. At baseline, CYFRA 21−1 levels were significantly higher in malignant versus benign nodules. Longitudinal mixed-effects modeling did not demonstrate statistically significant differences in trajectories between benign and malignant nodules. Benign nodules showed a small positive trend in log(CYFRA 21−1) whereas malignant nodules showed greater longitudinal variability. The magnitude of change assessed using the absolute slope of log(CYFRA 21−1) was significantly greater in malignant nodules compared with benign nodules (p < 0.05). Exploratory diagnostic analysis showed that baseline log(CYFRA 21−1) achieved and AUC of 0.68 (95% CI 0.56-0.79) with sensitivity 0.63 and specificity 0.71. The absolute slope of log(CYFRA 21−1) yielded an AUC of 0.67 (95% CI 0.48-0.87) with sensitivity 0.39 and specificity 0.97. Conclusions: CYFRA 21−1 exhibits substantial within-patient variability over time, with trajectories that reflect disease state and treatment. These findings suggest that longitudinal monitoring of CYFRA 21−1 may provide additional information beyond single time-point measurements in the evaluation of pulmonary nodules. Further studies in large prospective cohorts are warranted to validate these findings before clinical implementation.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Background: Lung cancer remains the leading cause of cancer mortality, yet blood-based biomarkers are not routinely used in diagnosis. This study evaluated four commercial blood protein assays, originally validated for other indications, in indeterminate pulmonary nodules (IPN). Methods: Using a prospective specimen collection, retrospective blinded evaluation design, samples were collected from patients with screening-detected, incidental, or symptomatic IPNs. Cytokeratin 19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and human epididymis protein 4 (HE-4) concentrations were quantified on commercial immunoassays. Logistic regression models were developed using internal training (Train), external testing (Test), and combined reestimation (Train + Test) cohorts and externally validated in an outcome-blinded multicenter cohort (Lung Team Project-2, LTP-2). Results: This study included 816 patients: 371 in Train, 166 in Test, and 279 in LTP-2. Malignancy rates were 54%, 44%, and 64%, respectively. In Train + Test, the area under the receiver operating curve (AUC) for lung cancer was 0.60 (95% confidence interval, 0.56–0.65) for CYFRA 21-1, 0.62 (0.58–0.67) for CEA, 0.60 (0.55–0.65) for CA-125, and 0.65 (0.60–0.70) for HE-4. In LTP-2, AUCs were 0.63 (0.56–0.70), 0.64 (0.57–0.70), 0.48 (0.40–0.55), and 0.61 (0.54–0.68), respectively. Combining all four biomarkers yielded an AUC of 0.70 (0.65–0.74) in Train + Test and 0.61 (0.54–0.68) in LTP-2. Conclusions: In the first biomarker study reporting external validation in LTP-2, CYFRA 21-1, CEA, CA-125, and HE-4 demonstrated diagnostic value in IPNs. Impact: By leveraging commercial assays, this study highlights opportunities to enhance lung cancer risk stratification using widely available diagnostics that could be rapidly integrated into clinical workflows.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer
Background: Lung cancer remains the leading cause of cancer mortality, yet blood-based biomarkers are not routinely used in diagnosis. This study evaluated four commercial blood protein assays, originally validated for other indications, in indeterminate pulmonary nodules (IPN). Methods: Using a prospective specimen collection, retrospective blinded evaluation design, samples were collected from patients with screening-detected, incidental, or symptomatic IPNs. Cytokeratin 19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), and human epididymis protein 4 (HE-4) concentrations were quantified on commercial immunoassays. Logistic regression models were developed using internal training (Train), external testing (Test), and combined reestimation (Train + Test) cohorts and externally validated in an outcome-blinded multicenter cohort (Lung Team Project-2, LTP-2). Results: This study included 816 patients: 371 in Train, 166 in Test, and 279 in LTP-2. Malignancy rates were 54%, 44%, and 64%, respectively. In Train + Test, the area under the receiver operating curve (AUC) for lung cancer was 0.60 (95% confidence interval, 0.56–0.65) for CYFRA 21-1, 0.62 (0.58–0.67) for CEA, 0.60 (0.55–0.65) for CA-125, and 0.65 (0.60–0.70) for HE-4. In LTP-2, AUCs were 0.63 (0.56–0.70), 0.64 (0.57–0.70), 0.48 (0.40–0.55), and 0.61 (0.54–0.68), respectively. Combining all four biomarkers yielded an AUC of 0.70 (0.65–0.74) in Train + Test and 0.61 (0.54–0.68) in LTP-2. Conclusions: In the first biomarker study reporting external validation in LTP-2, CYFRA 21-1, CEA, CA-125, and HE-4 demonstrated diagnostic value in IPNs. Impact: By leveraging commercial assays, this study highlights opportunities to enhance lung cancer risk stratification using widely available diagnostics that could be rapidly integrated into clinical workflows.
- Open Access
Longitudinal Analysis of CYFRA 21-1 Levels in Patients with Pulmonary Nodules: Differential Trajectories Between Benign and Malignant Cases and Impact of Tumor Resection
Background CYFRA 21-1, a cytokeratin-19 fragment, is a validated serum biomarker for non-small cell lung cancer (NSCLC). However, most studies rely on single time-point measurements, limiting its specificity in differentiating malignancy from benign pulmonary conditions. Inspired by the clinical utility of serial PSA measurements in prostate cancer, we investigated whether longitudinal trends in CYFRA 21-1 could enhance diagnostic and monitoring capabilities in patients with pulmonary nodules Methods and Findings We analyzed 132 patients with pulmonary nodules, including 41 with lung cancer and 91 with benign diagnoses. CYFRA 21-1 levels were measured serially using electrochemiluminescence assays. Longitudinal trends were assessed using linear mixed-effects models to estimate biomarker trajectories. Subgroup analyses examined differences between benign, untreated cancer, and post-treatment cancer groups, as well as within-patient changes in a subset of 16 cancer patients with both pre- and post-surgical measurements. Log-transformed data were used for the analysis. At baseline, CYFRA 21-1 levels were significantly higher in malignant versus benign nodules. Over time, CYFRA trajectories diverged: benign cases showed slight increases, whereas cancer patients exhibited greater biomarker volatility. In treated cancer patients, trend of CYFRA levels on the natural log scale decline from –0.00137 pre-surgery to –0.00263 to post-surgery, and both cancer groups showed significantly higher absolute slopes than the benign group (p < 0.05). While pre- vs post-treatment slope differences did not reach significance (p = 0.211), the general pattern indicated that CYFRA 21-1 is a dynamic marker responsive to tumor presence and removal. Conclusions CYFRA 21-1 exhibits substantial within-patient variability over time, with trajectories that reflect disease state and treatment. These findings suggest that longitudinal monitoring of CYFRA 21-1—analogous to PSA velocity in prostate cancer—may offer improved diagnostic and prognostic insight in the evaluation of pulmonary nodules. Further studies in larger cohorts are warranted to validate these findings and explore clinical implementation of CYFRA trajectory analysis.
Open AccessLongitudinal Analysis of CYFRA 21-1 Levels in Patients with Pulmonary Nodules: Differential Trajectories Between Benign and Malignant Cases and Impact of Tumor Resection
Background CYFRA 21-1, a cytokeratin-19 fragment, is a validated serum biomarker for non-small cell lung cancer (NSCLC). However, most studies rely on single time-point measurements, limiting its specificity in differentiating malignancy from benign pulmonary conditions. Inspired by the clinical utility of serial PSA measurements in prostate cancer, we investigated whether longitudinal trends in CYFRA 21-1 could enhance diagnostic and monitoring capabilities in patients with pulmonary nodules Methods and Findings We analyzed 132 patients with pulmonary nodules, including 41 with lung cancer and 91 with benign diagnoses. CYFRA 21-1 levels were measured serially using electrochemiluminescence assays. Longitudinal trends were assessed using linear mixed-effects models to estimate biomarker trajectories. Subgroup analyses examined differences between benign, untreated cancer, and post-treatment cancer groups, as well as within-patient changes in a subset of 16 cancer patients with both pre- and post-surgical measurements. Log-transformed data were used for the analysis. At baseline, CYFRA 21-1 levels were significantly higher in malignant versus benign nodules. Over time, CYFRA trajectories diverged: benign cases showed slight increases, whereas cancer patients exhibited greater biomarker volatility. In treated cancer patients, trend of CYFRA levels on the natural log scale decline from –0.00137 pre-surgery to –0.00263 to post-surgery, and both cancer groups showed significantly higher absolute slopes than the benign group (p < 0.05). While pre- vs post-treatment slope differences did not reach significance (p = 0.211), the general pattern indicated that CYFRA 21-1 is a dynamic marker responsive to tumor presence and removal. Conclusions CYFRA 21-1 exhibits substantial within-patient variability over time, with trajectories that reflect disease state and treatment. These findings suggest that longitudinal monitoring of CYFRA 21-1—analogous to PSA velocity in prostate cancer—may offer improved diagnostic and prognostic insight in the evaluation of pulmonary nodules. Further studies in larger cohorts are warranted to validate these findings and explore clinical implementation of CYFRA trajectory analysis.